Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, GINKGO BIOWORKS HOLDINGS, INC. reported revenue of $170M, down 25.1% year over year. Operating margin was -185.3% and net margin -183.8%, on a free-cash-flow margin of -105.0% with capital expenditure at 4.5% of revenue. Every figure is computed directly from DNA's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $170M | -185.3% | -183.8% |
| FY2024 | $227M | -246.5% | -240.9% |
| FY2023 | $251M | -343.8% | -355.1% |
| FY2022 | $478M | -462.4% | -440.6% |
| FY2021 | $314M | -582.6% | -583.1% |
How does DNA compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.